论文部分内容阅读
目的：探讨巴曲抗栓酶治疗心源性脑栓塞的疗效及安全性。方法：根据症状、体征，并经ＣＴ或ＭＲＩ证实有脑梗死影像表现，且有心房颤动病史的住院病人６例，其中男性２例，女性４例，年龄５９±ｓ１２ａ。巴曲抗栓酶１０ＢＵ溶于０．９％氯化钠注射液１００ｍＬ中８０ｍｉｎ静脉滴完，隔日１次，共６次，溶栓期间未用其他影响脑细胞功能药物。结果：２ｗｋ后全部病例均有效。治愈４例次，显效３例次，有效１例次。首剂应用距发病时间６ｈ内，效果较好，无１例出现副作用。结论：巴曲抗栓酶是一种安全、有效的治疗心源性脑栓塞药物，宜在早期、足量、长程应用。
Objective: To investigate the efficacy and safety of batroxobin in the treatment of cardioembolism. Methods: According to the symptoms and signs, 6 cases of hospitalized patients with history of atrial fibrillation were confirmed by CT or MRI, including 2 males and 4 females, aged 59 ± s12a. Batroxobin 10BU dissolved in 100mL of 0.9% sodium chloride injection intravenously 80min 80min, every other day, a total of 6 times, during thrombolysis did not affect other brain cell functional drugs. Results: All cases were effective after 2 weeks. 4 cases were cured, markedly effective in 3 cases, 1 case effective. The first dose application within 6h from the onset, the effect is better, no side effects occurred in 1 case. Conclusion: Batroxobin is a safe and effective treatment of cardioembolic drugs, should be early, adequate, long-term application.